Daniel Liu BA , Benjamin D. Hu BS , Jacob Glickman MD, Ross O’Hagan MD, Helen He MD, Emma Guttman-Yassky MD, PhD
{"title":"人工智能在特应性皮炎中的应用综述。","authors":"Daniel Liu BA , Benjamin D. Hu BS , Jacob Glickman MD, Ross O’Hagan MD, Helen He MD, Emma Guttman-Yassky MD, PhD","doi":"10.1016/j.jaci.2025.06.028","DOIUrl":null,"url":null,"abstract":"<div><div>Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by substantial clinical heterogeneity, posing significant challenges to clinicians in diagnosis, severity stratification, and management. Artificial intelligence (AI) has emerged as a transformative tool in medicine and dermatology, offering innovative solutions for disease screening, severity grading, and personalized therapeutic optimization. In AD, machine learning models have been utilized to identify novel biomarkers for therapeutic development, leading to more effective, safer, and AD-specific therapies. Additionally, these models have demonstrated the ability to diagnose AD and differentiate it from other dermatologic conditions, reducing reliance on subjective clinical assessments. Future integration of AI tools into clinical practice, such as leveraging real-time transcriptomic and proteomic data to predict optimal therapeutics, monitor treatment responses, and develop AI-embedded wearable technology for remote and continuous disease monitoring, can rapidly transform AD management. However, as technology advances, ensuring bias reduction through representative training data sets and establishing proper regulatory oversight to protect patient safety and privacy will be critical for its successful and widespread adoption. As AI continues to revolutionize AD management, its integration into clinical practice holds the potential to improve diagnostic accuracy, enhance personalized treatment approaches, and bridge health care disparities, ultimately improving human health.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 4","pages":"Pages 889-898"},"PeriodicalIF":11.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence in atopic dermatitis: A narrative review\",\"authors\":\"Daniel Liu BA , Benjamin D. Hu BS , Jacob Glickman MD, Ross O’Hagan MD, Helen He MD, Emma Guttman-Yassky MD, PhD\",\"doi\":\"10.1016/j.jaci.2025.06.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by substantial clinical heterogeneity, posing significant challenges to clinicians in diagnosis, severity stratification, and management. Artificial intelligence (AI) has emerged as a transformative tool in medicine and dermatology, offering innovative solutions for disease screening, severity grading, and personalized therapeutic optimization. In AD, machine learning models have been utilized to identify novel biomarkers for therapeutic development, leading to more effective, safer, and AD-specific therapies. Additionally, these models have demonstrated the ability to diagnose AD and differentiate it from other dermatologic conditions, reducing reliance on subjective clinical assessments. Future integration of AI tools into clinical practice, such as leveraging real-time transcriptomic and proteomic data to predict optimal therapeutics, monitor treatment responses, and develop AI-embedded wearable technology for remote and continuous disease monitoring, can rapidly transform AD management. However, as technology advances, ensuring bias reduction through representative training data sets and establishing proper regulatory oversight to protect patient safety and privacy will be critical for its successful and widespread adoption. As AI continues to revolutionize AD management, its integration into clinical practice holds the potential to improve diagnostic accuracy, enhance personalized treatment approaches, and bridge health care disparities, ultimately improving human health.</div></div>\",\"PeriodicalId\":14936,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology\",\"volume\":\"156 4\",\"pages\":\"Pages 889-898\"},\"PeriodicalIF\":11.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0091674925007389\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674925007389","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Artificial intelligence in atopic dermatitis: A narrative review
Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by substantial clinical heterogeneity, posing significant challenges to clinicians in diagnosis, severity stratification, and management. Artificial intelligence (AI) has emerged as a transformative tool in medicine and dermatology, offering innovative solutions for disease screening, severity grading, and personalized therapeutic optimization. In AD, machine learning models have been utilized to identify novel biomarkers for therapeutic development, leading to more effective, safer, and AD-specific therapies. Additionally, these models have demonstrated the ability to diagnose AD and differentiate it from other dermatologic conditions, reducing reliance on subjective clinical assessments. Future integration of AI tools into clinical practice, such as leveraging real-time transcriptomic and proteomic data to predict optimal therapeutics, monitor treatment responses, and develop AI-embedded wearable technology for remote and continuous disease monitoring, can rapidly transform AD management. However, as technology advances, ensuring bias reduction through representative training data sets and establishing proper regulatory oversight to protect patient safety and privacy will be critical for its successful and widespread adoption. As AI continues to revolutionize AD management, its integration into clinical practice holds the potential to improve diagnostic accuracy, enhance personalized treatment approaches, and bridge health care disparities, ultimately improving human health.
期刊介绍:
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.